Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes

  • Nuñez Carpintero, Iker|||0000-0002-2637-5236
  • Rigau, Maria|||0000-0002-6501-7212
  • Bosio, Mattia
  • O’Connor, Emily
  • Spendiff, Sally
  • Capella Gutiérrez, Salvador|||0000-0002-0309-604X
  • Cirillo, Davide|||0000-0003-4982-4716
  • Valencia, Alfonso|||0000-0002-8937-6789
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases., The authors acknowledge the donors and families, Daniel Rico (Newcastle University) for his contribution in early stages of the project, Anaïs Baudot (Aix Marseille Université and Barcelona Supercomputing Center) for her careful revision of the manuscript, Miguel Vázquez (Barcelona Supercomputing Center) for advising about Rbbt analysis, Jon Sánchez-Valle (Barcelona Supercomputing Center) and Núria Olvera (Barcelona Supercomputing Center and IDIBAPS) for the insightful discussions. The authors also acknowledge the corresponding funding institutions: The NeurOmics and RD-Connect projects have been funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreements no 2012-305121 and 2012-305444. I.N.C. was supported by a grant for pre-doctoral contracts for the training of doctors (Project ID: SEV-2015-0493-18-2) (Grant ID: PRE2018-083662) from the Spanish Ministry for Science, Innovation and Universities, and the EU project EVENFLOW under Horizon Europe agreement No. 101070430. E.O. was supported by an AFM-Téléthon postdoctoral fellowship for the duration of this work. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). V.G. was a research fellow of the Alexander von Humboldt Foundation. D.C. was supported by the European Commission’s Horizon 2020 Program, H2020-SC1-DTH-2018- 1, iPC - individualizedPaediatricCure (ref. 826121)., Peer Reviewed, "Article signat per 18 autors/es: Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O’Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A. C. ’t Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella-Gutiérrez, Davide Cirillo, Hanns Lochmüller & Alfonso Valencia "
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes

  • Nuñez Carpintero, Iker
  • Rigau, Maria
  • Bosio, Mattia
  • O’Connor, Emily
  • Spendiff, Sally
  • Capella Gutiérrez, Salvador
  • Cirillo, Davide
  • Valencia, Alfonso
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases., The authors acknowledge the donors and families, Daniel Rico (Newcastle University) for his contribution in early stages of the project, Anaïs Baudot (Aix Marseille Université and Barcelona Supercomputing Center) for her careful revision of the manuscript, Miguel Vázquez (Barcelona Supercomputing Center) for advising about Rbbt analysis, Jon Sánchez-Valle (Barcelona Supercomputing Center) and Núria Olvera (Barcelona Supercomputing Center and IDIBAPS) for the insightful discussions. The authors also acknowledge the corresponding funding institutions: The NeurOmics and RD-Connect projects have been funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreements no 2012-305121 and 2012-305444. I.N.C. was supported by a grant for pre-doctoral contracts for the training of doctors (Project ID: SEV-2015-0493-18-2) (Grant ID: PRE2018-083662) from the Spanish Ministry for Science, Innovation and Universities, and the EU project EVENFLOW under Horizon Europe agreement No. 101070430. E.O. was supported by an AFM-Téléthon postdoctoral fellowship for the duration of this work. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). V.G. was a research fellow of the Alexander von Humboldt Foundation. D.C. was supported by the European Commission’s Horizon 2020 Program, H2020-SC1-DTH-2018- 1, iPC - individualizedPaediatricCure (ref. 826121)., Peer Reviewed, "Article signat per 18 autors/es: Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O’Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A. C. ’t Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella-Gutiérrez, Davide Cirillo, Hanns Lochmüller & Alfonso Valencia ", Postprint (published version)